HAVN Life Sciences Inc
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psil… Read more
HAVN Life Sciences Inc (HAVLF) - Net Assets
Latest net assets as of January 2023: $837.82K USD
Based on the latest financial reports, HAVN Life Sciences Inc (HAVLF) has net assets worth $837.82K USD as of January 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.38 Million) and total liabilities ($540.44K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $837.82K |
| % of Total Assets | 60.79% |
| Annual Growth Rate | 28.55% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 335.21 |
HAVN Life Sciences Inc - Net Assets Trend (2020–2022)
This chart illustrates how HAVN Life Sciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HAVN Life Sciences Inc (2020–2022)
The table below shows the annual net assets of HAVN Life Sciences Inc from 2020 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-04-30 | $3.14 Million | -76.21% |
| 2021-04-30 | $13.20 Million | +594.21% |
| 2020-04-30 | $1.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to HAVN Life Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5282418100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $49.15 Million | 1564.92% |
| Other Comprehensive Income | $6.28 Million | 199.87% |
| Other Components | $575.13K | 18.31% |
| Total Equity | $3.14 Million | 100.00% |
HAVN Life Sciences Inc Competitors by Market Cap
The table below lists competitors of HAVN Life Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SysGroup PLC
LSE:SYS
|
$1.48K |
|
CARAVEL MIN
BE:STC
|
$1.48K |
|
HAPPY WORLD PROPERTY LTD
SEM:HWP
|
$1.48K |
|
TULLOW OIL (TQW.SG)
STU:TQW
|
$1.48K |
|
AFRICAN DOMESTIC BOND FUND ETF - (USD)
SEM:ADBF
|
$1.47K |
|
LAPTRUST IMARA I-REIT
XNAI:LAPTRUST
|
$1.47K |
|
Namliong SkyCosmos Inc
PINK:NLSC
|
$1.47K |
|
Egypt for Poultry
EGX:EPCO
|
$1.47K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HAVN Life Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 13,199,908 to 3,140,917, a change of -10,058,991 (-76.2%).
- Net loss of 22,443,548 reduced equity.
- New share issuances of 1,999,755 increased equity.
- Other comprehensive income increased equity by 160,968.
- Other factors increased equity by 10,223,834.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-22.44 Million | -714.55% |
| Share Issuances | $2.00 Million | +63.67% |
| Other Comprehensive Income | $160.97K | +5.12% |
| Other Changes | $10.22 Million | +325.5% |
| Total Change | $- | -76.21% |
Book Value vs Market Value Analysis
This analysis compares HAVN Life Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-04-30 | $0.85 | $0.00 | x |
| 2021-04-30 | $3.68 | $0.00 | x |
| 2022-04-30 | $0.73 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HAVN Life Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -714.55%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8117.81%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.29x
- Recent ROE (-714.55%) is below the historical average (-315.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -2.13% | 0.00% | 0.00x | 1.02x | $-230.72K |
| 2021 | -230.16% | -10988.64% | 0.02x | 1.08x | $-31.70 Million |
| 2022 | -714.55% | -8117.81% | 0.07x | 1.29x | $-22.76 Million |
Industry Comparison
This section compares HAVN Life Sciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HAVN Life Sciences Inc (HAVLF) | $837.82K | -2.13% | 0.65x | $1.47K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |